Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 750

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 750
---
,700 |   |
| Net change in cash                                                                 |     |              |  (14,132 | ) |     |              | (203,451 | ) |
| Cash, beginning of the year                                                        |     |              |   16,868 |   |     |              |  204,464 |   |
| Cash, end of the year                                                              |     | $            |    2,736 |   |     | $            |    1,013 |   |
| Supplemental disclosure of noncash investing and financing activities              |     |              |          |   |     |              |          |   |
| Increase in investment held in Trust Account through issuance of promissory note   |     | $            |   45,191 |   |     | $            |  150,000 |   |
| Remeasurement adjustment on class A ordinary shares subject to possible redemption |     | $            |  124,162 |   |     | $            |  803,885 |   |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. F-38

Denali Capital Acquisition Corp.

Notes to Unaudited Consolidated Financial Statements

NOTE 1 – ORGANIZATION AND BUSINESS OPERATION

Denali Capital Acquisition Corp. (the “Company” or “Denali”) is a newly organized blank check company incorporated in the Cayman
Islands on January 5, 2022. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses (a “Business
Combination”).

As of March 31, 2025, the Company had not commenced any operations. All activity for the period from January 5, 2022
(inception) through March 31, 2025, relates to the Company’s organizational activities, those necessary to prepare for and complete the initial public offering (“IPO”), identifying a target company for a business combination,
and activities in connection with an initial business combination, including with respect to our proposed business combination with Semnur Pharmaceuticals, Inc (“Semnur”). The Company does not expect to generate any operating revenues
until after the completion of an initial Business Combination. The Company is generating non-operating income in the form of income from the investment of proceeds derived from the IPO. The Company has
selected December 31 as its fiscal year end.

The